Inogen Inc ((INGN)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Inogen’s latest earnings call struck an optimistic tone, highlighting a company in the midst of a strategic turnaround. Management emphasized rising volumes, improving profitability metrics and a fortified balance sheet, while acknowledging persistent pressure in U.S. channels and the absence of GAAP profitability.
Revenue Growth and Unit Volume Expansion
Inogen reported Q4 2025 revenue of about $82 million, up 2% year over year, with full‑year revenue rising 4% to $348.7 million. More telling was unit volume growth above 20% in both the quarter and full year, as demand for portable oxygen concentrators and conversions from tanks accelerated.
International Business Strength
International operations were a key bright spot, with Q4 revenue of $32.5 million growing roughly 15% year over year. For 2025, international POC sales climbed about 18.4%, supported by expanding HME relationships and successful tenders that deepened Inogen’s global footprint.
Return to Adjusted EBITDA Profitability
The company returned to adjusted EBITDA profitability for the first time since 2021, posting $2.7 million for full‑year 2025. Q4 adjusted EBITDA was still negative at $1.7 million but represented a sharp improvement from a $3.6 million loss a year earlier.
Substantial Reduction in Adjusted Net Loss
Loss metrics continued to trend in the right direction, with full‑year adjusted net loss narrowing to $8 million, a 60.6% improvement from 2024. GAAP net loss improved as well, shrinking 36.6% year over year to $22.7 million.
Strong Balance Sheet and Capital Return Plan
Inogen closed 2025 with $120.9 million in cash, equivalents, marketable securities and restricted cash, and no debt, up $3.4 million from the prior year. Backed by this liquidity, the board approved a $30 million share repurchase program to be executed over 2026–2027.
Product Innovation and Portfolio Diversification
Management highlighted a transformation from a single‑product POC player into a multi‑product respiratory care platform spanning oxygen, sleep therapy, airway clearance and digital health. New offerings include the limited‑release Simeox system, the Voxi 5 stationary concentrator, Aurora CPAP masks and an Inogen patient portal.
Early Commercial Traction for New Products
New products are beginning to contribute, with Simeox generating more than $6 million in global 2025 revenue, mostly from international cash‑pay markets, and receiving strong clinical and commercial feedback. Voxi showed solid sequential growth after launch, while Aurora masks posted high patient satisfaction in studies and are rolling out through B2B channels.
Expanded Addressable Market and Long-Term Targets
The broadened portfolio has expanded Inogen’s estimated total addressable market from about $400 million to roughly $3.4 billion across airway clearance, stationary oxygen and sleep masks. Against this backdrop, management is targeting high single‑digit revenue growth and at least 10% adjusted EBITDA within 3–5 years, supported by at least one new product launch annually.
Operating Expense Discipline
Cost control remains a focus, with Q4 operating expenses at $44.5 million and adjusted operating expenses reduced to $41.4 million from $43.7 million a year earlier. That 5.2% decline demonstrates expense discipline even as the company continues to invest in R&D and commercial launches.
U.S. Sales and Direct-to-Consumer Pressure
Domestic performance lagged international growth, as U.S. Q4 sales fell 5.1% year over year to $36.1 million. The direct‑to‑consumer channel remained under pressure, though sequential declines moderated from a 27% drop in Q1 to a 15% decline by Q4.
Rental Revenue Decline
Rental revenue continued to soften, slipping 4.5% year over year in Q4 to $13.1 million. Management tied this to a mix shift toward payers with lower reimbursement and a reduced number of patients on service.
Gross Margin Compression
Profitability at the gross margin level tightened, with Q4 2025 gross margin at 43.1%, down 220 basis points year over year, and full‑year margin at 44.2%, down 190 basis points. The company attributed roughly two‑thirds of the pressure to channel mix, as more POC units were sold to business customers at lower margins.
Order Timing and Timing-Related Revenue Pressure
Results were also affected by the timing of several large customer orders that shifted from Q4 into the first half of 2026 due to budget constraints. Management estimated this timing impact at a few hundred basis points of Q4 revenue, with some orders expected to be recognized gradually through the first half of 2026.
Quarterly Profitability Uncertainty
While Inogen expects to remain adjusted‑EBITDA positive on a full‑year basis, management stopped short of promising profitability every quarter in 2026. Seasonality and planned incremental investments in R&D and commercialization could push individual quarters into negative territory.
Continued GAAP Losses
Despite clear operational progress, Inogen is still operating in the red on a GAAP basis, with a full‑year 2025 net loss of $22.7 million and a Q4 loss of $7.1 million. Management positioned these losses as manageable given improving trends and the strength of the balance sheet.
Channel Mix and Short-Term Headwinds
The company’s shift toward B2B sales and higher POC penetration in new patient starts, now estimated at about 59% versus roughly 40% historically, is reshaping the business. While this benefits B2B growth, it is putting near‑term pressure on legacy DTC and rental channels as the mix continues to evolve.
Forward-Looking Guidance and Strategic Outlook
Looking ahead to 2026, Inogen guided revenue to a range of $366 million to $373 million, implying about 6% growth at the midpoint and flat year‑over‑year revenue in Q1. The company expects mid‑single‑digit growth in B2B POCs, continued rental declines, full‑year positive adjusted EBITDA and longer‑term high single‑digit growth with double‑digit adjusted EBITDA, supported by margin‑accretive product launches and the $30 million share repurchase.
Inogen’s earnings call painted the picture of a company restoring growth momentum while methodically rebuilding profitability. For investors, the combination of strong international performance, a larger addressable market, disciplined spending and a cash‑rich, debt‑free balance sheet offers a cautiously constructive setup, even as U.S. channels, margins and GAAP losses remain key watch points.